Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuchi Gulati

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Medrxiv : the Preprint Server for Health Sciences|November 28, 2024
AI-Powered cellular morphometric biomarkers discovered in needle biopsy of prostatic cancer predict neoadjuvant androgen deprivation therapy response and prognosis: an international multicenter retrospective studyHong Yan, April W Mao, Dan Li, et al.
The Journal of Clinical Investigation|April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profilesPedro Barata, Shuchi Gulati, Andrew Elliott, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Genome-Wide Variations of End Motif in Cell-Free DNA Fragments Distinguish Immunotherapy Responders from Non-Responders in Head and Neck Cancer: A Multi-Institute Prospective StudyRavi Bandaru, Hailu Fu, Haizi Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2022
Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L Leddon, Shuchi Gulati, Sulsal Haque, et al.
The Journal of Clinical Investigation|May 19, 2026
Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancerRavi Bandaru, Hailu Fu, Haizi Zheng, et al.
Cancer Letters|March 26, 2026
AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumorsHong Yan, April W Mao, Dan Li, et al.
The Journal of Clinical Investigation|July 15, 2024
Molecular analysis of primary and metastatic sites in patients with renal cell carcinomaShuchi Gulati, Pedro C Barata, Andrew Elliott, et al.
Biorxiv : the Preprint Server for Biology|January 31, 2024
Copper drives remodeling of metabolic state and progression of clear cell renal cell carcinomaMegan E Bischoff, Behrouz Shamsaei, Juechen Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell CarcinomaPedro Barata, Catherine Tangen, Melissa Plets, et al.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Medrxiv : the Preprint Server for Health Sciences|November 28, 2024
AI-Powered cellular morphometric biomarkers discovered in needle biopsy of prostatic cancer predict neoadjuvant androgen deprivation therapy response and prognosis: an international multicenter retrospective studyHong Yan, April W Mao, Dan Li, et al.
The Journal of Clinical Investigation|April 23, 2024
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profilesPedro Barata, Shuchi Gulati, Andrew Elliott, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Genome-Wide Variations of End Motif in Cell-Free DNA Fragments Distinguish Immunotherapy Responders from Non-Responders in Head and Neck Cancer: A Multi-Institute Prospective StudyRavi Bandaru, Hailu Fu, Haizi Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2022
Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and NeckJennifer L Leddon, Shuchi Gulati, Sulsal Haque, et al.
The Journal of Clinical Investigation|May 19, 2026
Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancerRavi Bandaru, Hailu Fu, Haizi Zheng, et al.
Cancer Letters|March 26, 2026
AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumorsHong Yan, April W Mao, Dan Li, et al.
The Journal of Clinical Investigation|July 15, 2024
Molecular analysis of primary and metastatic sites in patients with renal cell carcinomaShuchi Gulati, Pedro C Barata, Andrew Elliott, et al.
Biorxiv : the Preprint Server for Biology|January 31, 2024
Copper drives remodeling of metabolic state and progression of clear cell renal cell carcinomaMegan E Bischoff, Behrouz Shamsaei, Juechen Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell CarcinomaPedro Barata, Catherine Tangen, Melissa Plets, et al.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Pageof 5